Assessment of proarrhythmic activity of chloroquine in in vivo and ex vivo rabbit models
- PMID: 23759957
- PMCID: PMC3669570
- DOI: 10.4103/0976-500X.110892
Assessment of proarrhythmic activity of chloroquine in in vivo and ex vivo rabbit models
Abstract
Objectives: To evaluate the prolongation of ventricular repolarization and proarrhythmic activity of antimalarial drug chloroquine in two rabbit proarrhythmia models viz., in vivo α1 adrenoceptor-stimulated anesthetized rabbit and ex vivo isolated Langendorff rabbit heart using clofilium as standard proarrhythmic agent.
Materials and methods: In the in vivo model, three groups of rabbits, anesthetized by pentobarbitone sodium and α-chloralose, sensitized with α1 agonist methoxamine followed by either continuous infusion of saline (control) or clofilium (3 mg/kg) or chloroquine (21 mg/kg) for 30 min. In ex vivo model, rabbit hearts were perfused with clofilium (10 μM) or chloroquine (300 μM) continuously after priming along with methoxamine, acetylcholine chloride and propranolol hydrochloride.
Results: In these models, prolongation of repolarization during α1-adrenoceptor stimulation produced early after depolarization (EAD) and Torsade de pointes (TdP). Saline infusion did not induce any abnormality in the animals. Clofilium caused expected changes in the electrocardiogram in both the models including TdP (50.0% in in vivo and 66.67% in ex vivo). Chloroquine caused decrease in heart rate and increase in the corrected QT (QTc) interval in both the models. Further, apart from different stages of arrhythmia, TdP was evident in 33.33% in ex vivo model, whereas no TdP was observed in in vivo model.
Conclusions: The results indicated that proarrhythmic potential of chloroquine and clofilium was well evaluated in both the models; moreover, both the models can be used to assess the proarrhythmic potential of the new drug candidates.
Keywords: chloroquine; clofilium; ex vivo rabbit model; in vivo rabbit model; torsade de pointes; α1 -Adrenoceptor stimulation.
Conflict of interest statement
Figures


Similar articles
-
K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.Eur J Pharmacol. 2007 Jan 19;555(1):54-60. doi: 10.1016/j.ejphar.2006.10.005. Epub 2006 Oct 17. Eur J Pharmacol. 2007. PMID: 17112502
-
Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes.Br J Pharmacol. 2002 Feb;135(4):1003-12. doi: 10.1038/sj.bjp.0704550. Br J Pharmacol. 2002. PMID: 11861329 Free PMC article.
-
Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits.J Pharmacol Exp Ther. 2008 Jun;325(3):875-81. doi: 10.1124/jpet.108.137729. Epub 2008 Mar 5. J Pharmacol Exp Ther. 2008. PMID: 18322148
-
Drug-induced long QT syndrome: Concept and nonclinical models for predicting the onset of drug-induced torsade de pointes in patients in compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E14/S7B guidance.J Pharmacol Exp Ther. 2025 Feb;392(2):100023. doi: 10.1124/jpet.124.002184. Epub 2024 Nov 22. J Pharmacol Exp Ther. 2025. PMID: 40023597 Review.
-
Disturbances of cardiac wavelength and repolarization precede Torsade de Pointes and ventricular fibrillation in Langendorff perfused rabbit hearts.Prog Biophys Mol Biol. 2016 May;121(1):3-10. doi: 10.1016/j.pbiomolbio.2016.03.004. Epub 2016 Mar 12. Prog Biophys Mol Biol. 2016. PMID: 26980523 Review.
Cited by
-
Cardiac contractility modulation attenuates structural and electrical remodeling in a chronic heart failure rabbit model.J Int Med Res. 2020 Oct;48(10):300060520962910. doi: 10.1177/0300060520962910. J Int Med Res. 2020. PMID: 33044118 Free PMC article.
-
A comparative review on heart ion channels, action potentials and electrocardiogram in rodents and human: extrapolation of experimental insights to clinic.Lab Anim Res. 2021 Sep 8;37(1):25. doi: 10.1186/s42826-021-00102-3. Lab Anim Res. 2021. PMID: 34496976 Free PMC article. Review.
-
QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.J Interv Card Electrophysiol. 2020 Nov;59(2):337-345. doi: 10.1007/s10840-020-00822-x. Epub 2020 Jul 11. J Interv Card Electrophysiol. 2020. PMID: 32654098 Free PMC article.
-
Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.Arch Med Res. 2021 Apr;52(3):261-269. doi: 10.1016/j.arcmed.2020.11.006. Epub 2020 Nov 17. Arch Med Res. 2021. PMID: 33257051 Free PMC article. Review.
-
Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19.Clin Transl Sci. 2021 May;14(3):1133-1146. doi: 10.1111/cts.13011. Epub 2021 Apr 9. Clin Transl Sci. 2021. PMID: 33620150 Free PMC article.
References
-
- Woosley RL. Drugs that prolong the QT interval and/or induce Torsades de pointes (Arizon CERT web site) [Last accessed on 2012 March 02]. Available from: http://www.azcert.org/medical-pros/drug-lists/browse-drug-list.cfm .
-
- Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drug: Clinical and regulatory implications. Report on a conference of the European society of cardiology. Eur Heart J. 2000;21:1216–31. - PubMed
-
- The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals ICH Topic S7B guideline. 2005 Nov; (CPMP/ICH/423/02)
-
- Morganroth J. Comparative efficacy of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmia. Am J Cardiol. 1987;60:1276–81. - PubMed
-
- Lawrence CL, Pollard CE, Hammond TG, Valentine JP. Non-clinical proarrhythmia models: Predicting torsades de pointes. J Pharmacol Toxicol Methods. 2005;52:46–59. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources